US FDA’s New ‘N of 1’ Guidance Essentially A Down Payment On Critical Advice

Draft guidance will help sponsor-investigators working on individualized gene therapies. The focus on basic administrative and procedural aspects of interaction with the FDA leaves many policy and commercialization questions about how these personalized investigational products should be studied unanswered.